**Supporting Statement: Part A**

**Monitoring Changes in Attitudes and Practices among Family Planning Providers and Clinics**

**Submitted by:**

Centers for Disease Control and Prevention (CDC)

National Center for Chronic Disease Prevention and Health Promotion

Division of Reproductive Health

Women’s Health and Fertility Branch

**Contact Person:**

Lauren B. Zapata, PhD, MSPH

Division of Reproductive Health

Centers for Disease Control and Prevention

4770 Buford Highway NE, MS K-34

Atlanta, GA 30341

Phone: 770-488-6358

Fax: 770-488-6391

Email: lzapata@cdc.gov

**May 13, 2013**

Table of Contents

[List of Attachments 4](#_Toc356238744)

[Acronyms 5](#_Toc356238745)

[A. JUSTIFICATION 6](#_Toc356238746)

[*A1. Circumstances Making the Collection of Information Necessary* 6](#_Toc356238747)

[Background 6](#_Toc356238748)

[Privacy Impact Assessment 8](#_Toc356238749)

[Overview of the Data Collection System 8](#_Toc356238750)

[Items of Information to be Collected 9](#_Toc356238751)

[Identification of Website(s) and Content Directed at Children Under 13 Years of Age 10](#_Toc356238752)

[*A2. Purpose and Use of the Information Collection* 10](#_Toc356238753)

[Privacy Impact Assessment Information 11](#_Toc356238754)

[*A3. Use of Improved Information Technology and Burden Reduction* 11](#_Toc356238755)

[*A4. Efforts to Identify Duplication and Use of Similar Information* 12](#_Toc356238756)

[*A5. Impact on Small Businesses or Other Small Entities* 12](#_Toc356238757)

[*A6. Consequences of Collecting the Information Less Frequently* 12](#_Toc356238758)

[*A7. Special Circumstances Relating to the Guidelines of 5 CRF 1320.5* 13](#_Toc356238759)

[*A8. Comments in Response to the FRN and Efforts to Consult Outside the Agency* 13](#_Toc356238760)

[A. Comments in Response to the FRN 13](#_Toc356238761)

[B. Efforts to Consult Outside the Agency 13](#_Toc356238762)

[*A9. Explanation of Any Payment of Gift to Respondents* 14](#_Toc356238763)

[*A10. Assurance of Confidentiality Provided to Respondents* 14](#_Toc356238764)

[IRB Approval 15](#_Toc356238765)

[Privacy Impact Assessment Information 15](#_Toc356238766)

[*A11. Justification for Sensitive Questions* 16](#_Toc356238767)

[*A12. Estimates of Annualized Burden Hours and Costs* 16](#_Toc356238768)

[*A13. Estimates of Other Total Annual Cost Burden to Respondents and Record Keepers* 17](#_Toc356238769)

[*A14. Annualized Cost to the Federal Government* 17](#_Toc356238770)

[*A15. Explanation for Program Changes or Adjustments* 18](#_Toc356238771)

[*A16. Plans for Tabulation and Publication and Project Time Schedule* 18](#_Toc356238772)

[*A17. Reason(s) Display of OMB Expiration Date is Inappropriate* 21](#_Toc356238773)

[*A18. Exceptions to Certification for Paperwork Reduction Act Submission* 22](#_Toc356238774)

[APPENDIX 1: Summary of survey constructs, survey numbers measuring each construct, and relevant U.S. family planning guidance document 23](#_Toc356238775)

[APPENDIX 2: Listing of parameters and statistical approach by objective 25](#_Toc356238776)

[References 42](#_Toc356238777)

# List of Attachments

Attachment A Section 301 of the Public Health Service Act (42 U.S.C. 241)

Attachment B-1 Federal Register Notice

Attachment B-2 Summary of public comments and CDC response

Attachment C-1 Private-sector initial cover letter (first contact)

Attachment C-2 Public-sector initial cover letter (first contact)

Attachment D-1 2013 Survey of Health Care Providers (i.e., *provider survey*)

Attachment D-2 Provider survey cover sheet

Attachment E-1 2013 Survey for Administrators of Publicly-Funded Health Centers that Provide Family Planning (i.e., *administrator survey)*

Attachment E-2 Administrator survey cover sheet

Attachment F-1 Private-sector reminder postcard for provider survey (second contact)

Attachment F-2 Public-sector reminder postcard for provider survey (second contact)

Attachment F-3 Public-sector reminder postcard for administrator survey (second contact)

Attachment G-1 Private-sector follow-up cover letter (third contact)

Attachment G-2 Public-sector follow-up cover letter for provider survey (third contact)

Attachment G-3 Public-sector follow-up cover letter for administrator survey (third contact)

# Acronyms

AAFP American Academy of Family Physicians

AAP American Academy of Pediatrics

ACOG American College of Obstetricians and Gynecologists

AMA American Medical Association

ASRM American Society for Reproductive Medicine

CDC Centers for Disease Control and Prevention

FRN Federal Register Notice

HRSA/BPHC Health Resources and Services Administration/Bureau of Primary Health Care

ICR Information Collection Request

IIF Information in identifiable form

IRB Institutional Review Board

NACHC National Association of Community Health Centers

NCCDPHP National Center for Chronic Disease Prevention and Health Promotion

NFPRHA National Family Planning and Reproductive Health Association

OPA Office of Population Affairs

PPFA Planned Parenthood Federation of America

QFPS *Guidance for Proving Quality Family Planning Services*

US MEC *U.S. Medical Eligibility Criteria for Contraceptive Use*

US SPR  *U.S. Selected Practice Recommendations for Contraceptive Use*

WHO SPR *World Health Organization Selected Practice Recommendations for Contraceptive Use*

1. **JUSTIFICATION**

## *A1. Circumstances Making the Collection of Information Necessary*

### Background

This Information Collection Request (ICR) is new, and represents a collaborative effort between the Centers for Disease Control and Prevention (CDC) and the HHS Office of Population Affairs (OPA). CDC needs to collect data about family planning practices among private-sector physicians and public-sector providers after releasing one set of national CDC contraceptive guidelines and before releasing a second set of national CDC contraceptive guidelines. At the same time, OPA needs to collect baseline information about family planning practices among public-sector providers and health center administrators before the release of revised national programmatic guidelines developed to serve federal grantees. Given that both agencies need to collect data from public-sector providers about family planning practices, CDC and OPA chose to collaborate, reduce survey burden in the field, and strengthen the quality of the overall data collection effort.

Unintended pregnancy rates remain high in the United States; about 50% of all pregnancies are unintended, with higher proportions among adolescents and young women, women of racial and ethnic minorities, and women with less education and lower incomes.[1](#_ENREF_1) Unintended pregnancies increase risk for poor maternal and infant outcomes,[2](#_ENREF_2) and cost the United States about $5 billion a year.[3](#_ENREF_3) About half of unintended pregnancies are among women who were not using contraception at the time they became pregnant; the other half are among women who became pregnant despite reported use of contraception.[4](#_ENREF_4) Therefore, strategies to prevent unintended pregnancy should include assisting women at risk to choose appropriate contraceptive methods and helping women use methods correctly and consistently to prevent pregnancy. One way to achieve these strategies is to adapt or develop contraceptive guidance to improve delivery of services in the United States.

The *U.S. Medical Eligibility Criteria for Contraceptive Use* (US MEC), the first national guidance on family planning containing evidence-based recommendations for the safe use of contraceptive methods for women and men with specific characteristics and medical conditions, was published by the CDC in June 2010.[5](#_ENREF_5) The US MEC is intended to assist health-care providers when they counsel women, men, and couples about contraceptive method choice, and is meant to be a source of clinical guidance; policy-makers, program managers, and the scientific community may also be users of the guidance.

The *U.S. Selected Practice Recommendations for Contraceptive Use* (US SPR), currently being adapted from the *World Health Organization’s Selected Practice Recommendations for Contraceptive Use* (WHO SPR),[6](#_ENREF_6), [7](#_ENREF_7) is expected to be published by the CDC in 2013. The US SPR will provide guidance for how to use contraceptive methods safely and effectively once they are deemed to be medically appropriate, and will address common, yet controversial contraceptive management questions. The US SPR is intended to assist health-care providers when they counsel women, men and couples about contraceptive method use, and is meant to be a source of clinical guidance; policy-makers, program managers, and the scientific community may also be users of the guidance.

The *Guidance for Providing Quality Family Planning Services* (QFPS), currently being developed by the CDC, in collaboration with OPA, is expected to be published by the CDC in 2013. The QFPS will update OPA’s *Program Guidelines for Project Grants for Family Planning Services* last issued in 2001,[8](#_ENREF_8) and will provide evidence-informed recommendations to improve client care and service delivery infrastructure to support the provision of quality family planning services to women and men of reproductive age in the United States. The QFPS is primarily intended to assist family planning providers funded through OPA’s Federal Title X Family Planning Program, but may also be of value to other providers of family planning services in non-Title X settings, as well as other primary care providers. The QFPS is meant to be a source of clinical guidance; policy-makers and program managers may also be users of the guidance.

These guidance documents (i.e., US MEC, US SPR, QFPS) have been (US MEC) or will be (US SPR, QFPS) widely disseminated to health-care providers and other constituents, via professional organizations, federal program grantees, scientific and programmatic meetings, scientific manuscripts, online resources, and other avenues, as deemed appropriate.

To monitor changes in provider and clinic attitudes and practices over time, we initiated a multi-phase assessment, including baseline data collection, in December 2009 (Phase 1) (EPI AID No. 2010-024; OMB No. 0920-0008). Data from private- and public-sector family planning providers throughout the United States were collected by mail from December 2009 through March 2010.

This proposed information collection represents Phase II of the multi-phase assessment. Follow-up data will be collected pertaining to the awareness of the US MEC, use of US MEC provider tools (e.g., US MEC iPhone/iPad application), and changes in provider attitudes and practices around recommendations included in the US MEC (e.g., the safety and effectiveness of combined hormonal contraceptives for women with bariatric surgery via restrictive procedures). Additionally, baseline data pertaining to the US SPR and QFPS will be collected.

The proposed information collection will fill a gap in knowledge related to the awareness of the US MEC, use of US MEC provider tools that have been developed by CDC, and changes in provider attitudes and practices around recommendations included in the US MEC. It will also enable CDC and OPA to assess baseline attitudes and practices related to topics that will be addressed in the forthcoming US SPR and QFPS. Additionally, the information collected will allow CDC and OPA to improve family planning-related public health practice, as CDC and OPA will tailor future dissemination activities and develop needed provider tools based upon the results. OMB approval is requested for one year.

CDC plans to submit a separate information collection request to OMB for a follow-up survey in about three years.

Authority for CDC to collect this data is granted by Section 301 of the Public Health Service Act (42 U.S.C. 241) **(Attachment A)**.

### Privacy Impact Assessment

#### Overview of the Data Collection System

We seek to administer mailed surveys to a random sample of 10,000 private- and public-sector family planning providers and health center administrators in the United States. Private-sector physicians will be randomly selected from a sampling frame with individual-level information on physicians. To reach public-sector providers and health center administrators, publicly funded health centers that provide family planning services will be randomly selected from a sample frame with health center-level information. At sampled health centers, one provider and one administrator will be asked to complete surveys. More specifically, we seek to have surveys completed by:

* 2,000 private-sector office-based physicians (i.e., those specializing in obstetrics/gynecology, family medicine, and adolescent medicine), sampled from the American Medical Association (AMA) Physician Masterfile;
* 2,000 providers from Title X clinics, sampled from the Guttmacher Institute database of publicly funded family planning health centers; and
* 2,000 providers from non-Title X clinics, sampled from the Guttmacher Institute database of publicly funded family planning health centers.
* 2,000 clinic administrators from Title X clinics, sampled from the Guttmacher Institute database of publicly funded family planning health centers; and
* 2,000 clinic administrators from non-Title X clinics, sampled from the Guttmacher Institute database of publicly funded family planning health centers.

Each sampled private-sector physician and public-sector health center will receive a mailed survey package. The mailed survey package will include a cover letter (Attachments C-1 and C-2) addressed personally to the physician or health center, and will include a description of the assessment, will address the importance of participation, and will include a point of contact to direct inquiries. The cover letters will also include signatures of support from partner organizations (i.e., American Academy of Family Physicians [AAFP], American Academy of Pediatrics [AAP], American College of Obstetricians and Gynecologists [ACOG], American Society for Reproductive Medicine [ASRM], Health Resources and Services Administration/Bureau of Primary Health Care [HRSA/BPHC], National Association of Community Health Centers [NACHC], National Family Planning and Reproductive Health Association [NFPRHA], and Planned Parenthood Federation of America [PPFA]).

For private-sector physicians, each mailed survey package will include a single survey (**Attachment D-1**) with survey cover sheet (**Attachment D-2**), to be completed by the physician.

For public-sector health centers, each mailed survey package will include two surveys (**Attachments D-1 and E-1**) with two survey cover sheets (**Attachments D-2 and E-2**) – one to be completed by a clinician who provides family planning services to women of reproductive age at least twice per week, and the second to be completed by a health center administrator. Each respondent will only be asked to complete a single survey.

Each survey will contain a unique identification number (UID), assigned by the data collection contractor. CDC will not have access to any file linking names and addresses of physicians and health centers in our sample with their assigned UIDs. Each mailed survey will be accompanied by a postage-paid return envelope addressed to the contractor via a rented postal office box. Respondents will also be given the option to complete the survey online via a password-protected web-based data collection system.

Anticipating non-response, a reminder postcard will be sent to those who have not responded to the first mailing after approximately 2-4 weeks (Attachments F-1, F-2, and F-3). A second copy of the survey, along with a follow-up cover letter (Attachments G-1, G-2, and G-3) will be sent to those who have not responded to the first survey or reminder postcard approximately 2-4 weeks after the reminder postcard. Phone calls will be made and emails sent (if email addresses are available) to those who have not responded to any of the contact attempts to encourage participation.

Data collected online will be downloaded into an electronic database on a regular basis. Paper-copy survey data will be entered into an electronic database. The two databases, stripped of any identifiers other than the UID, will be permanent federal records and will be maintained in accordance with CDC’s records control schedule (<http://isp-v-maso-apps/RecSched/ViewSchedule.aspx?RID=29>). Paper-copy surveys will be shredded within eight months after completion of data entry. Respondents will not be re-contacted after survey completion to validate any potentially unclear data elements.

#### Items of Information to be Collected

Although no information in identifiable form (IIF) will be collected via the survey, IIF will be used to mail the survey packages to sampled physicians and health centers. Specifically, CDC project staff will obtain health center names, addresses, phone numbers, and email addresses (where available), from the Guttmacher Institute (the data collection contractor will obtain the names and contact information for private-sector physicians). This information will be provided to our contractor to implement the survey. The contractor will assign a UID to each survey being sent out for completion, and use this UID for tracking purposes. The contractor will maintain the sole file linking names of physicians and health centers with UIDs. At no time will CDC have access to linked data or know if a specific health center or physician has responded or not. Information collection will be conducted according to a security plan developed in consultation with NCCDPHP’s Office of Informatics and Information Resources.

#### Identification of Website(s) and Content Directed at Children Under 13 Years of Age

The information collection system will include a web-based data collection method option that is password-protected. Individuals may choose to complete the survey online, as an alternative to completing the paper-copy survey and returning by postal mail. No person under 13 years old will access the website.

## *A2. Purpose and Use of the Information Collection*

The purposes of this ICR are:

* To understand the current use of contraceptive guidelines in practice and valued sources of contraceptive information, including awareness and use of the US MEC*;*
* To describe provider attitudes and practices related to contraceptive method use by women with specific characteristics or medical conditions approximately three years after the release of the US MEC, and assess changes from baseline levels (for provider types for which baseline data were collected);
* To establish baseline attitudes and practices related to select contraceptive practices to be addressed in the forthcoming US SPR and QFPS;
* To describe differences in attitudes and practices between various family planning providers (e.g. private- and public-sector providers); and
* To identify gaps between evidence and practice to inform development of educational interventions and provider tools to improve future contraceptive service delivery.

The data will primarily be used by CDC and OPA to assess changes in family planning provider attitudes and practices from before to after the release of the US MEC, and to assess current attitudes and practices around contraceptive issues to be addressed by the forthcoming US SPR and QFPS. To assess changes in attitudes and practices that occur after the release of the US SPR and QFPS, CDC and OPA are planning additional data collection in about two and a half to three years, for which an ICR will be submitted at a later date. The *practical utility* of the information to be collected is to optimize the translation of the evidence-based recommendations into widespread practice, by allowing CDC and OPA, in collaboration with key partner organizations, to target available resources in ways that will foster and promote future awareness and adoption of the guidance into practice (e.g., additional dissemination activities, development of educational interventions and provider tools to address gaps between evidence and attitudes and practices).

The *negative consequences* of not having the information would be potential underutilization of the practice guidelines, which require extensive federal resources to develop and maintain, and the implementation of less effective practices in the field. Other key partner organizations supporting the data collection that may also choose to use the results generated by this data collection to enhance translation of research into practice include AAFP, AAP, ACOG, ASRM, HRSA/BPHC, NACHA, NFPRHA, and PPFA. However, these organizations will not have access to the data. The data may be used on an ongoing basis (i.e., not limited to a given frequency).

Although this is a new ICR, similar information pertaining to the US MEC was collected during the Phase I assessment conducted December 2009 – March 2010 (EPI AID No. 2010-024; OMB No. 0920-0008). Data from this information collection activity resulted in useful knowledge of differences in contraceptive method availability between public- and private-sector providers, differences in attitudes and practices of family planning providers based on varying levels of key demographic characteristics (e.g., years since completion of formal health-care training), and identification of attitudes and practices that are not consistent with current scientific evidence (e.g., misconceptions that intrauterine devices are not safe for adolescent or nulliparous women). The *rationale for continuing the data collection* pertaining to the US MEC is to assess changes in provider attitudes and practices approximately three years after the release of the US MEC, and to identify persisting differences between provider types and persisting misconceptions that may warrant continued and more tailored dissemination and educational activities.

### Privacy Impact Assessment Information

No IIF will be collected via the survey, but IIF will be used to send sampled physicians and health centers mailed survey packages. The IIF to be used will include physician and health center names, mailing addresses, phone numbers, and email addresses (where available). The information will be obtained from the appropriate sample frames (e.g., AMA Physician Masterfile, Guttmacher Institute database of publicly funded family planning health centers). The IIF will only be shared with the contractor implementing the surveys, for the purposes of sending out the mailed survey packages and tracking responses. The contractor will assign a UID to each survey sent out for completion, and use this UID to log responses. At no time will CDC have access to identifiable data or know if a specific provider or health center has responded or not. No sensitive information will be collected, so the proposed data collection activity will have little or no effect on the respondent’s privacy. The data collection contractor will work closely with CDC’s National Center for Chronic Disease Prevention and Health Promotion’s Office of Informatics and Information Resources to ensure that technical and security standards, processes and procedures are followed.

## *A3. Use of Improved Information Technology and Burden Reduction*

Every individual asked to complete a survey will be given the option of completing the survey online via a password-protected web-based data collection system. The basis for this decision was to decrease costs and transcription errors associated with paper-copy survey data entry, and because increasingly, more health care providers are choosing to complete surveys online. There is also literature to support that mixed-mode survey options improve response rates among physicians.[9](#_ENREF_9)

For those opting to complete the web-based survey, questions that are not applicable to a respondent based on an answer to a previous question, will be automatically skipped. For those opting to complete the paper-copy survey, questions that are not applicable to a respondent based on an answer to a previous question, will be skipped via formatting and skip patterns. Both options are designed to minimize burden to the respondent and obtain data as efficiently as possible. We do not anticipate that the burden estimates will vary depending on the format of the survey completed. Also, we will only collect the minimum information necessary for the purposes of the ICR.

## *A4. Efforts to Identify Duplication and Use of Similar Information*

Although there are some studies that have queried and reported on attitudes and practices of family planning providers related to contraceptive use (mostly intrauterine contraception), among women with certain characteristics or medical conditions,[10-14](#_ENREF_10) these studies were conducted among non-nationally representative samples, did not cover the full range of methods, practices and attitudes being proposed for measurement in this ICR, and were non-specific to the US MEC.

Similar information, pertaining to the US MEC only, was collected by CDC December 2009 through March 2010 (Phase 1) (EPI AID No. 2010-024; OMB No. 0920-0008), where baseline data on specific provider attitudes and practices before the release of the US MEC were assessed. These data do not meet the current needs of the proposed ICR (Phase II), which in part seeks to monitor changes in attitudes and practices related to recommendations included in the US MEC, approximately three years after its release. Previously collected data also do not meet the current needs of the proposed ICR as they do not include information on the US SPR or the QFPS.

There are no national-level data available that are similar to those being proposed in this ICR. This was confirmed via literature searches of electronic databases, and discussions with stakeholders and federal partners.

## *A5. Impact on Small Businesses or Other Small Entities*

Data will be collected from family planning providers in the private- and public-sectors. The questions have been held to the absolute minimum required for the intended use of the data.

The survey instruments will be presented in a clear and easy to complete format based on previous surveys and recommendations from survey methodology research. Sampled individuals will be able to complete the survey at their leisure, and will answer only questions about themselves and the practice at which they received the survey. The burden of participation in this survey for providers and clinic administrators will not affect the normal functioning of the entities in which they work.

## *A6. Consequences of Collecting the Information Less Frequently*

Baseline data for the US MEC (Phase 1) were collected December 2009 through March 2010. This was the first of a multi-phase data collection effort to monitor changes in family planning provider attitudes and practices around recommendations included in the US MEC. Phase II of the assessment (the current ICR) seeks to collect follow-up information on the US MEC approximately three years after its release, as well as baseline data on attitudes and practices related to the forthcoming US SPR and QFPS. We plan to conduct Phase III approximately two and a half years to three years after the release of the US SPR and QFPS. There are currently no plans to conduct further assessments after Phase III.

Conducting assessments approximately two and a half to three years after the release of the guidance documents allows time for changes to occur in provider attitudes and practices. Since the data will be used to tailor future dissemination activities, and develop needed provider tools to optimize widespread adoption and use of the guidance documents, this assessment interval is adequate to characterize issues of concern (e.g., large gaps between science and practice) without losing timeliness of data. Collection of information less frequently would prevent timely identification of issues that limit full or accurate use of the guidance, thereby preventing development of beneficial provider tools and inhibiting necessary public health program planning.

## *A7. Special Circumstances Relating to the Guidelines of 5 CRF 1320.5*

This request fully complies with the regulation 5 CFR 1320.5.

## *A8. Comments in Response to the FRN and Efforts to Consult Outside the Agency*

### Comments in Response to the FRN

The 60-day Federal Register Notice was published in the Federal Register on April 9, 2012, Vol. 77, No. 68, pp. 2 (**Attachment B-1**). One non-substantive public comment was received on April 9, 2012; CDC’s standard response was sent (**Attachment B-2**).

### Efforts to Consult Outside the Agency

Per DHHS and OMB’s strong encouragement for DHHS agencies to collaborate together to meet mutual and related data needs, CDC and OPA are closely collaborating on this ICR (see section A1 – Background). CDC sought consultation on methodology and survey instrumentation outside of the agency from individuals listed in the below table.

| **Year Consulted** | **Name, Title, Agency** | **Email / Phone #** |
| --- | --- | --- |
| 2012 | Marilyn Keefe, Deputy Assistant Secretary, OPA | Marilyn.Keefe@hhs.gov; 240 453.2805 |
| 2012 | Christina LaChance, OPA | Christina.LaChance@os.hhs.gov; 240 453.2813 |
| 2012 | Nancy Mautone-Smith, Public Health Consultant, OPA | Nancy.Mautone-Smith@hhs.gov;  |
| 2012 | Sue Moskosky, Director, Office of Family Planning, OPA | Susan.Moskosky@hhs.gov; 240.453.2888 |
| 2012 | Courtney Benedict, PPFA | (650) 574-5823 |
| 2012 | Clare Coleman, Executive Director, NFPRHA | (202) 293-3114 |
| 2012 | Jan Chapin, Associate Director, ACOG | jchapin@acog.org |
| 2012 | Jennifer Deitrich, Assistant Professor Department of Obstetrics and Gynecology, Baylor College of Medicine | jedietri@texaschildrens.org; 832-826-7464 |
| 2012 | Linda Dominguez, Chair, Association of Reproductive Health Professionals | linda-dominguez@swcp.com; (505) 379-0290 |
| 2012 | David Eisenberg, Assistant Professor of Obstetrics & Gynecology, Washington University in Saint Louis | eisenbergd@wudosis.wustl.edu  |
| 2012 | Jennifer Frost, Senior Research Associate, Guttmacher Institute | jfrost@guttmacher.org; 212-248-1111  |
| 2012 | Marji Gold, Professor, Albert Einstein College of Medicine | Marji.Gold@einstein.yu.edu  |
| 2012 | Mark Hathaway, Unity Health Care and Washington Hospital Center | (202) 715-7901 |
| 2012 | Andy Kaunitz, University of Florida, Jacksonville | Andrew.Kaunitz@jax.ufl.edu  |
| 2012 | Melissa Kottke, Emory University | MKOTTKE@emory.edu  |
| 2012 | Arik Marcel, Johns Hopkins University | amarcell@jhsph.edu  |
| 2012 | Deborah Nucatola, PPFA | 202-973-4800 |
| 2012 | Michael Policar, UCSF Bixby Center | michael.policar@cdph.ca.gov |
| 2012 | Diana Taylor, UCSF Bixby Center  | diana.taylor@nursing.ucsf.edu; (510) 986-8950 |
| 2012 | Maria Trent, Associate Professor of Pediatrics, Johns Hopkins School of Medicine | mtrent2@jhmi.edu; 443.287.8945 |

## *A9. Explanation of Any Payment of Gift to Respondents*

To encourage participation, as well as to provide important family planning information and provider tools, a package of “US MEC provider tools” will be sent to all physicians returning a survey (complete or non-complete), as well as all health centers returning at least one survey (complete or non-complete). The materials will be distributed at the end of data collection. If project funds allow, all non-responding private-sector physicians and public-sector health centers will also receive a package of “US MEC provider tools”. The package may include the following: paper-copy US MEC MMWR and updates, US MEC color-coded and laminated summary chart, and US MEC wheel.

Justification for offering the materials as an incentive to participate in the data collection effort comes from literature examining methodologies for improving response rates among health care providers, including physicians, which typically have lower response rates. One systematic review that examined findings from 66 published reports of efforts to improve response rates to physician surveys found that offering an incentive resulted in improved response rates.[9](#_ENREF_9)

## *A10. Assurance of Confidentiality Provided to Respondents*

Survey cover letters will assure potential respondents that their answers will be maintained in a secure manner, and that results will only be released in summary form.

As previously described, although CDC will obtain IIF (e.g., names, addresses, phone numbers, email addresses [where available]) of physicians and health centers randomly selected to participate in the assessment from the appropriate sampling frames, this information will be given to the data collection contractor who will assign a unique identification number (UID) and use this UID to track responses.

CDC will not have access to any file linking the names and addresses of physicians and health centers with their UID. The contractor will be the sole source of a password-protected electronic file linking sampled physicians and health centers with their assigned UIDs. This list will be destroyed within eight months after the end of the data collection period. Survey data transmitted to CDC at the end of the data collection period will not contain any IIF; instead, only de-identified UIDs will be provided. The data collection contractor will work closely with CDC’s National Center for Chronic Disease Prevention and Health Promotion’s Office of Informatics and Information Resources to ensure that technical and security standards, processes and procedures are followed.

For the survey sent to public-sector health centers to be completed by a health center administrator, querying about clinic-level practices and protocols, it will not be necessary to identify the person completing the survey on behalf of the health center.

### IRB Approval

The proposed data collection was approved as non-research, public-health practice by the National Center for Chronic Disease Prevention and Health Promotion, and thus institutional review board (IRB) approval is not required.

### Privacy Impact Assessment Information

A. The Privacy Act does not apply based on the items of information collected and transmitted to CDC.

B. Safeguards will exist to minimize the possibility of unauthorized access, use, or dissemination of the information being collected. To transmit the names, addresses, phone numbers and email addresses of health centers selected to participate in the survey, CDC will use a password-protected electronic file to send the information to the contractor. The password to unlock the file will be provided to the contractor via telephone and not in written form.

After the contractor assigns a UID to each sampled physician/health center, the single file linking the identifiable information to the UID will be maintained in a password-protected electronic file, and destroyed within eight months after the end of data collection.

To track responses, the contractor will create a tracking database that only contains the UIDs, and not the IIF. When it is time to make follow-up contacts to non-respondents (e.g., reminder postcards, second survey package mailings), the contractor will create a list of UIDs who have yet to respond, based on information available in the tracking database. These UIDs will be provided to a contractor staff member who has access to the file with IIF, who will initiate the follow-up contract efforts. Data ultimately transmitted to CDC will contain no IIF.

C. Potential respondents will be informed about the voluntary nature of participation in the cover letter that accompanies the survey (**Attachments C-1 and C-2**). Completion of a survey will be considered consent.

D. The voluntary nature of the survey will be described to the potential participants in the cover letter that will accompany the surveys asking individuals to participate (**Attachments C-1 and C-2**)**.**

## *A11. Justification for Sensitive Questions*

No sensitive questions will be included.

## *A12. Estimates of Annualized Burden Hours and Costs*

A. The table below summarizes the estimated annualized burden hours. The 2012-2013 Survey of Health Care Providers is provided as **Attachment D-1**. The 2012-2013 Survey of Administrators of Publicly Funded Health Centers that Provide Family Planning Services is provided as **Attachment E-1**. CDC estimates that the provider survey will take on average 15 minutes to complete, and the administrator survey will take between 20 to 40 minutes to complete. This was estimated by having various project staff members and external colleagues not familiar with the instruments complete the surveys.

| **Type of Respondent** | **Form Name** | **No. of Respondents** | **No. Responses per Respondent** | **Average Burden per Response (in hours)** | **Total Burden Hours** |
| --- | --- | --- | --- | --- | --- |
| Office-based physicians (private sector) | 2012-2012 Survey of Health Care Providers | 2,000 | 1 | 15/60 | 500 |
| Title X clinic providers (public sector) | 2012-2012 Survey of Health Care Providers | 2,000 | 1 | 15/60 | 500 |
| Non-Title X clinic providers (public sector) | 2012-2012 Survey of Health Care Providers | 2,000 | 1 | 15/60 | 500 |
| Title X clinic administrators (public sector) | 2012-2013 Survey of Administrators of Publicly-Funded Health Centers that Provide Family Planning Services | 2,000 | 1 | 40/60 | 1,333 |
| Non-Title X clinic administrators (public sector) | 2012-2013 Survey of Administrators of Publicly-Funded Health Centers that Provide Family Planning Services | 2,000 | 1 | 40/60 | 1,333 |
|  | **TOTAL** | **4,166** |

B. The table below summarizes the estimated annualized burden costs. The estimates of hourly wages were obtained from the Department of Labor.[15](#_ENREF_15) The total estimated annualized cost to respondents is $149,080.

| **Type of Respondent** | **Form Name** | **No. of Respondents** | **No. Responses per Respondent** | **Average Burden per Response (in hours)** | **Total Burden Hours** | **Average Hourly Wage** | **Total Cost** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Office-based physicians (private sector) | 2012-2012 Survey of Health Care Providers | 2,000 | 1 | 15/60 | 500 | $76.88 | $38,440 |
| Title X clinic providers (public sector) | 2012-2012 Survey of Health Care Providers | 2,000 | 1 | 15/60 | 500 | $32.42 | $16,210 |
| Non-Title X clinic providers (public sector) | 2012-2012 Survey of Health Care Providers | 2,000 | 1 | 15/60 | 500 | $32.42 | $16,210 |
| Title X clinic administrators (public sector) | 2012-2013 Survey of Administrators of Publicly-Funded Health Centers that Provide Family Planning Services | 2,000 | 1 | 40/60 | 1,334 | $29.34 | $39,110 |
| Non-Title X clinic administrators (public sector) | 2012-2013 Survey of Administrators of Publicly-Funded Health Centers that Provide Family Planning Services | 2,000 | 1 | 40/60 | 1,334 | $29.34 | $39,110 |
|  | Total | $149,080 |

## *A13. Estimates of Other Total Annual Cost Burden to Respondents and Record Keepers*

There are no costs to respondents other than their time.

## *A14. Annualized Cost to the Federal Government*

This ICR will be funded through a contract with Manila in the amount of $1,129,518. The sources of this funding will come from CDC’s Division of Reproductive Health ($729,518) and the Office of Population Affairs ($400,000). The contract task will include salaries and supplies.

Personnel costs of federal employees involved in oversight of the contract, technical assistance, and analysis of data (i.e., direct costs to the federal government) will include those of 11 CDC/DRH staff (1 project lead at .375FTE and 10 additional staff at .125FTE).

The total estimated annual cost to the government is $1,286,788.

|  |  |  |
| --- | --- | --- |
| **Expense Type** | **Expense Explanation** | **Annual Costs (dollars)** |
| Federal government staff salaries  | Project lead | GS-13 | .375 FTE | $32,063 |
| Project staff  | GS-14 | .125 FTE | $12,629 |
| Project staff  | GS-15 | .125 FTE | $14,856 |
| Project staff  | GS-13 | .125 FTE | $10,688 |
| Project staff | GS-13 | .125 FTE | $10,688 |
| Project staff | GS-13 | .125 FTE | $10,688 |
| Project staff  | GS-14 | .125 FTE | $12,629 |
| Project staff | GS-13 | .125 FTE | $10,688 |
| Project staff  | GS-14 | .125 FTE | $12,629 |
| Project staff  | GS-15 | .125 FTE | $14,856 |
| Project staff | GS-15 | .125 FTE | $14,856 |
| Contract with Manila Consulting |  | $1,129,518 |
| **TOTAL** |  | **$1,286,788** |

\*Salary estimates were estimated from 2012 Federal Pay Rates (<http://www.fedsmith.com/pay_rates/>)

## *A15. Explanation for Program Changes or Adjustments*

This is a new data collection.

## *A16. Plans for Tabulation and Publication and Project Time Schedule*

Our analytic plans are described below by objective. Please refer to Appendix 1 in this document for a summary of survey constructs, survey question numbers measuring each construct, and relevant U.S. family planning guidance documents for each construct. Additionally, please refer to Appendix 2 in this document for a more detailed listing of each major parameter of interest and statistical approach to be used.

In addition to the analytic plans described by objective below, we will describe our sample by demographic and training characteristics using questions #1-12 on the phase 2 provider survey, and questions #1-8, 22-24 on the phase 2 administrator survey.

*Objective 1: To understand the current use of contraceptive guidelines in practice and valued sources of contraceptive information, including awareness and use of the US MEC.*

* We will analyze questions #28, 31-33 on the phase 2 provider survey, and question #25 on the phase 2 administrator survey.
* We will generate descriptive frequencies for each response option of each question.
* For the questions from the provider survey, frequencies will be generated for the entire sample collectively, as well as stratified by provider type (i.e., private-sector OB/GYN, private-sector family medicine physician, private-sector adolescent medicine physician, public-sector Title X clinic provider, and public-sector non-Title X clinic provider). We may also compare private-sector providers with public-sector providers.
* For the question from the administrator survey, frequencies will be generated for the entire sample collectively, as well as stratified by public-sector Title X clinic administrator, and public-sector non-Title X clinic administrator.
* To examine differences between subgroups, bivariate analyses will be conducted using the appropriate statistical test. For example, to examine differences in the percent of providers not knowing about the US MEC before participation in the survey (#31; coded as yes/no), chi-square tests will be computed.

*Objective 2: To describe provider attitudes and practices related to contraceptive method use by women with specific characteristics or medical conditions approximately three years after the release of the US MEC, and assess changes from baseline levels (for provider types for which baseline data were collected).*

* To describe current provider attitudes and practices:
	1. We will analyze questions #13-16 and 19-21 on the phase 2 provider survey.
	2. We will generate descriptive frequencies for each response option of each question. For attitudinal questions, we plan to collapse the response options of ‘very safe’ and ‘safe’ together, as well as collapse the response options of ‘unsafe’ and ‘very unsafe’ together.
	3. Frequencies will be generated for the entire sample collectively, as well as stratified by provider type (i.e., private-sector OB/GYN, private-sector family medicine physician, private-sector adolescent medicine physician, public-sector Title X clinic provider, and public-sector non-Title X clinic provider). We may also compare private-sector providers with public-sector providers.
	4. To examine differences between subgroups, bivariate analyses will be conducted using the appropriate statistical test. For example, to examine differences in provider perceptions of the safety of IUDs for nulliparous women, we will conduct a chi-square test comparing the distributions of ‘very safe/safe’, ‘unsafe/very unsafe’ and ‘don’t know’ by provider type. Those responding ‘don’t know’ may also be deleted from the analysis, or combined with the ‘unsafe/very unsafe’ group. Findings will be considered statistically significant if the p-value is <0.05.
* To assess changes from baseline levels:
	1. We will analyze questions #13, 15-16 and 19-21 on the phase 2 provider survey, and questions #15-22 from the phase 1 provider survey.
	2. We will generate descriptive frequencies for each response option. For attitudinal questions, we plan to collapse the response options of ‘very safe’ and ‘safe’ together, as well as collapse the response options of ‘unsafe’ and ‘very unsafe’ together. Those responding ‘don’t know’ will either be deleted from the analysis or combined with the ‘unsafe/very unsafe’ group.
	3. We will compare estimates from phase 1 and phase 2 by conducting chi-square tests examining each attitude or practice by time (coded as phase 1 or phase 2). Findings will be considered statistically significant if the p-value is <0.05. We expect that most statistically significant changes will also represent conceptually significant changes. A change of 10-20% that is statistically significant will in general also be conceptually important. However, the percent change that will be considered conceptually important is dependent on the parameter being assessed and the size of the denominator. For example, a 10% improvement in the prevalence of adolescent medicine physicians reporting that IUDs are safe for adolescents may or may not be statistically significant due to smaller numbers of such providers in our sample, but may be considered conceptually significant. Comparisons between phase 1 and phase 2 will be done for the entire sample collectively (excluding public-sector non-Title X clinic providers who were not included in phase 1), as well as stratified by provider types included in both phases (i.e., private-sector OB/GYN, private-sector family medicine physician, private-sector adolescent medicine physician, and public-sector Title X clinic provider). We may also compare private-sector providers with public-sector providers.
	4. Although we will be unable to conclusively attribute any positive changes observed to the dissemination of the US MEC, we will also examine changes between phase 1 and phase 2 (collectively, and by provider type) stratified by both awareness of the US MEC (#31 in the phase 2 provider survey) and use of any of the US MEC provider tools (#32 in the phase 2 provider survey).

*Objective 3: To establish baseline attitudes and practices related to select contraceptive practices to be addressed in the forthcoming US SPR and QFPS.*

* We will analyze questions #17-18, 22-27, 29-30 on the phase 2 provider survey, and questions #9-22 on the phase 2 administrator survey.
* We will generate descriptive frequencies for each response option of each question.
* For the questions from the provider survey, frequencies will be generated for the entire sample collectively, as well as stratified by provider type (i.e., private-sector OB/GYN, private-sector family medicine physician, private-sector adolescent medicine physician, public-sector Title X clinic provider, and public-sector non-Title X clinic provider). We may also compare private-sector providers with public-sector providers.
* For the questions from the administrator survey, frequencies will be generated for the entire sample collectively, as well as stratified by public-sector Title X clinic administrator, and public-sector non-Title X clinic administrator.
* To examine differences between subgroups, bivariate analyses will be conducted using the appropriate statistical test. For example, to examine differences in provider perceptions of the safety of quick start for combined hormonal contraceptives, we will conduct a chi-square test comparing the distributions of ‘very safe/safe’, ‘unsafe/very unsafe’ and ‘don’t know’ by provider type. Those responding ‘don’t know’ may also be deleted from the analysis, or combined with the ‘unsafe/very unsafe’ group. Findings will be considered statistically significant if the p-value is <0.05.

*Objective 4: To describe differences in attitudes and practices between various family planning providers (e.g. private- and public-sector providers).*

* Described above and in more detail in Appendix 2 – please see:
	1. Objective 1, parameters 1b, 2b, 2d, 3b, and 5b;
	2. Objective 2, parameters 1b, 2b, 3b, 4b, 5b, 6b, and 7b; and
	3. Objective 3, parameters 1b, 1d, 2b, 3b, 4b, 5b, 6b, 7b, 8b, 9b, 10b, 11b, 12b, 13b, 14b, 15b, 16b, 17b, 18b, 19b, 20b, 21b, 22b, 23b, 24b, 25b, 26b, 27b, 28b, 29b, 30b, 31b, 32b, 33b, 34b, 35b, 36b, 38b, 39b, 40b, 41b, 42b, and 43b

*Objective 5: To identify gaps between evidence and practice to inform development of educational interventions and provider tools to improve future contraceptive service delivery.*

* Generation of frequency distributions of the various attitudes and practices (described above) will allow project team members to identify attitudes and practices that are inconsistent with current evidence and recommendations in the various guidance documents. It may be that specific provider groups are targeted for educational interventions or receipt of provider tools.

Additionally, after exploring the data as described above, we also intend to conduct select multivariable analyses examining factors associated with key outcomes of interest. For example, we are interested in examining provider characteristics independently associated with quick start attitudes and practices, attitudes and practices surrounding provision of DMPA to adolescents, and attitudes and practices surrounding provision of IUDs to nulliparous women.

The anticipated project time schedule is outlined in the table below. Results will be available to the public health community via peer-reviewed publications. Developed provider tools will at a minimum be made available on the CDC/DRH website for downloading.

| **Activity** | **Time Schedule** |
| --- | --- |
| Survey packages sent to sampled providers/clinics | 2 weeks to 1 month after OMB approval |
| 2nd contact mailing (reminder postcard) to non-respondents | ~2-4 weeks after 1st contact mailing |
| 3rd contact mailing (repeat survey) to non-respondents | ~2-4 weeks after 2nd contact mailing |
| Phone/email follow-up contact to non-respondents | 3-9 months after OMB approval |
| End data collection | 9-12 months after OMB approval |
| Data entry/validation of data | 12-15 months after OMB approval |
| Analyses of data | 15-36 months after OMB approval |
| Publication of findings | 24-36 months after OMB approval |

## *A17. Reason(s) Display of OMB Expiration Date is Inappropriate*

No such exception is requested. The OMB control number and expiration date will be displayed on the paper questionnaire and on the data collection internet site.

## *A18. Exceptions to Certification for Paperwork Reduction Act Submission*

There are no exceptions to the certification.

**APPENDIX 1**: **Summary of survey constructs, survey numbers measuring each construct, and relevant U.S. family planning guidance document**

| **Survey Construct** | **Survey Number** | **Evaluation Measure for:** |
| --- | --- | --- |
| **Phase 1 Provider Survey** | **Phase 2 Provider Survey** | **Phase 2 Administrator Survey** | **2010 US MEC\*** | **2013 US SPR\*** | **2013 QFPS\*** |
| *Safety Attitudes*  |  |  |  |  |  |  |
| COCs for women with certain characteristics | 15 | 13, 14 | -- | X | -- | -- |
| IUDs for women with certain characteristics | 16, 17 | 15 | -- | X | -- | X |
| DMPA for women with certain characteristics | 18 | 16 | -- | X | -- | -- |
| ‘Quick Start’ for CHCs  | -- | 17 | -- | -- | X | X |
| ‘Quick Start’ for DMPA | -- | 17 | -- | -- | X | X |
| ‘Quick Start’ for implants | -- | 17 | -- | -- | X | X |
| ‘Quick Start’ for IUDS | -- | 17 | -- | -- | X | X |
| *Practices* |  |  |  |  |  |  |
| DMPA for adolescents | 19 | 19 | -- | X | -- | -- |
| COC for postpartum women | 20 | 20 | -- | X | -- | -- |
| IUDs for nulliparous women | 21, 22 | 21 | -- | X | -- | X |
| ‘Quick Start’ for CHCs  | -- | 23 | -- | -- | X | X |
| ‘Quick Start’ for DMPA  | -- | 24 | -- | -- | X | X |
| Contraceptive counseling practices | -- | 18 | 13 | -- | -- | X |
| Required exams and tests  | -- | 22 | -- | -- | X | X |
| Recommended follow up | -- | 25 | -- | -- | X | -- |
| Emergency contraception  | -- | 26 | -- | -- | X | X |
| Dispensing year’s supply of pills at 1 visit | -- | 27 | -- | -- | X | X |
| Contraceptive method availability | 14 | -- | 9 | X | -- | X |
| Cervical cancer screening | -- | 29, 30 | -- | -- | -- | X |
| Family planning services provided | -- | -- | 10 | -- | -- | X |
| Referral practices | -- | -- | 11 | -- | -- | X |
| Preconception care services | -- | -- | 12 | -- | -- | X |
| *Sources of Information/Tools* |  |  |  |  |  |  |
| Preferred provider tools | 23 | -- | -- | X | X | X |
| Preferred continuing education sources | 24 | 28 | -- | X | X | X |
| *Awareness of Guidelines* |  |  |  |  |  |  |
| Awareness of US MEC, US SPR, or QFPS | 25 | 31 | 25 | X | X | X |
| Awareness of US MEC provider tools | -- | 32 | -- | X | -- | -- |
| Recommended new topics | -- | 33 | -- | X | -- | -- |
|  |  |  |  |  |  |  |
| *Health center systems and programs* |  |  |  |  |  |  |
| Hours of services | -- | -- | 14 | -- | -- | X |
| Educational materials provided | -- | -- | 14 | -- | -- | X |
| Adolescent services | -- | -- | 14,15 | -- | -- | X |
| Information technology | -- | -- | 16 | -- | -- | X |
| Community education programs | -- | -- | 17, 18 | -- | -- | X |
| Quality improvement systems | -- | -- | 19, 20 | -- | -- | X |
| Referral arrangements and networks | -- | -- | 21 | -- | -- | X |
| Staff training | -- | -- | 22 | -- | -- | X |
| *Demographics/Training* |  |  |  |  |  |  |
| Role | 1 | 6 | 23, 24 | Not specific evaluation measures, but used to better understand use of guidelines and to target dissemination efforts. |
| Clinical focus | 2 | 7 | 2 |
| Funding sources | 3 | 2 | -- |
| Setting | 4 | 1 | 1, 4 |
| State | 5 | 3 | 3 |
| # of clients | 8 | 9 | 5 |
| % provide family planning services | 9 | 10 | 6 |
| Time spent on family planning | 10 | -- | -- |
| Gender | 11 | 5 | -- |
| # providers in practice/clinic | -- | 4 | -- |
| Patient characteristics | 13 | 12 | 7 |
| # days formal family planning training | 6 | -- | -- |
| Years since last formal training | 7 | 8 | -- |
| Trained in LARC insertion | 12 | 11 | 22 |
| Health care network linkages | -- | -- | 8 |  |

\*US MEC=*U.S. Medical Eligibility Criteria for Contraceptive Use*; US SPR=*U.S. Selected Practice Recommendations for Contraceptive Use*; QFPS=*Guidance for Providing Quality Family Planning Services* (revised Title X programmatic guidelines).

**APPENDIX 2**: **Listing of Parameters and Statistical Approach By Objective**

| **PARAMETERS FOR OBJECTIVE 1** | **Statistical Approach** |
| --- | --- |
| Phase 2 Provider Survey Question #28 |
| 1a | What percent of providers reported that the following sources were an ‘important source’, ‘minor source’, and ‘not used’ for staying informed about recommended clinical practices related to contraception? [conferences, continuing education programs, discussions with colleagues, institutional practice protocols, journals, medication package inserts, online resources, professional organization publications or notifications, textbooks, US MEC, WHO MEC, WHO SPR, other] | Frequencies – overall and stratified by provider type |
| 1b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting that the following sources were an ‘important source’, ‘minor source’, and ‘not used’ for staying informed about recommended clinical practices related to contraception? [conferences, continuing education programs, discussions with colleagues, institutional practice protocols, journals, medication package inserts, online resources, professional organization publications for notifications, textbooks, US MEC, WHO MEC, WHO SPR, other] NOTE: Some response options may be collapsed (e.g., ‘important source’ and ‘minor source’). | Chi-square tests |
| Phase 2 Provider Survey Question #31 |
| 2a | What percent of providers reported that they learned about the 2010 US MEC via the following ways? [I did not know about the guidelines before participating in the survey, professional organization publications or notifications, conference attendance, continuing medical education programs, discussions with colleagues, email alert from CDC, institutional practice protocol, journals, online resources, textbooks, other] | Frequencies – overall and stratified by provider type |
| 2b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting that they learned about the 2010 US MEC via the following ways? [I did not know about the guidelines before participating in the survey, professional organization publications or notifications, conference attendance, continuing medical education programs, discussions with colleagues, email alert from CDC, institutional practice protocol, journals, online resources, textbooks, other] | Chi-square tests |
| 2c | What percent of providers reported that they learned about the 2013 US SPR via the following ways? [I did not know about the guidelines before participating in the survey, professional organization publications or notifications, conference attendance, continuing medical education programs, discussions with colleagues, email alert from CDC, institutional practice protocol, journals, online resources, textbooks, other] | Frequencies – overall and stratified by provider type |
| 2d | Are there significant (p<0.05) differences between provider types in the percent of providers reporting that they learned about the 2013 US SPR via the following ways? [I did not know about the guidelines before participating in the survey, professional organization publications or notifications, conference attendance, continuing medical education programs, discussions with colleagues, email alert from CDC, institutional practice protocol, journals, online resources, textbooks, other] | Chi-square tests |
| Phase 2 Provider Survey Question #32 |
| 3a | What percent of providers reported ever use of the following US MEC materials? [US MEC website, US MEC color-coded summary chart in English, US MEC color-coded summary chart in Spanish, US MEC wheel, US MEC iPhone/iPad application, US MEC 2011 update with revised recommendations for postpartum contraceptive use, US MEC 2012 update with revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV] | Frequencies – overall and stratified by provider type |
| 3b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting ever use of the following US MEC materials? [US MEC website, US MEC color-coded summary chart in English, US MEC color-coded summary chart in Spanish, US MEC wheel, US MEC iPhone/iPad application, US MEC 2011 update with revised recommendations for postpartum contraceptive use, US MEC 2012 update with revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV] | Chi-square tests |
| Phase 2 Provider Survey Question #33 |
| 4 | What percent of providers suggested specific additional medical conditions or patient characteristics to be included in the US MEC? (provider write-in responses) | Frequencies – overall and stratified by provider type |
| Phase 2 Administrator Survey Question #32 |
| 5a | What percent of clinic administrators reported various levels of awareness of the 2013 federal guidance entitled “Recommendations for Providing Quality Family Planning Services”? [‘not having heard of it’, ‘having heard about it, but not having read it’, and ‘having heard about it, and having read it’? | Frequencies – overall and stratified by clinic type |
| 5b | Are there significant differences between clinic types in the percent of clinic administrators reporting various levels of awareness of the 2013 federal guidance entitled “Recommendations for Providing Quality Family Planning Services”? [‘not having heard of it’, ‘having heard about it, but not having read it’, and ‘having heard about it, and having read it’? | Chi-square tests |

| **PARAMETERS FOR OBJECTIVE 2** | **Statistical Approach** |
| --- | --- |
| Phase 2 Provider Survey Question #13 |  |
| 1a | What percent of providers reported that COCs were ‘very safe’ or ‘safe’ versus ‘unsafe’ or ‘very unsafe’ versus ‘don’t know’ for the following groups of women *during Phase 2*? [Breastfeeding women ≥1 month postpartum without other risk factors for venous thromboembolism (VTE), Smokers 35 years of age or older, Obese women (BMI ≥30 kg/m2), Women with a history of bariatric surgery via restrictive procedures (e.g., vertical banded gastroplasty), Women with a history of bariatric surgery via malabsorptive procedures (e.g., Roux-en-Y gastric bypass), Women with rheumatoid arthritis, Women with inflammatory bowel disease (i.e., Ulcerative colitis, Crohn’s disease) without other risk factors for VTE] | Frequencies – overall and stratified by provider type |
| 1b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting that COCs were ‘very safe’ or ‘safe’ versus ‘unsafe’ or ‘very unsafe’ versus ‘don’t know’ for the following groups of women *during Phase 2*? [Breastfeeding women ≥1 month postpartum without other risk factors for venous thromboembolism (VTE), Smokers 35 years of age or older, Obese women (BMI ≥30 kg/m2), Women with a history of bariatric surgery via restrictive procedures (e.g., vertical banded gastroplasty), Women with a history of bariatric surgery via malabsorptive procedures (e.g., Roux-en-Y gastric bypass), Women with rheumatoid arthritis, Women with inflammatory bowel disease (i.e., Ulcerative colitis, Crohn’s disease) without other risk factors for VTE]. NOTE: Those responding ‘don’t know’ may also be deleted from the analysis, or combined with the ‘unsafe/very unsafe’ group.  | Chi-square tests  |
| 1c | Are there significant (p<0.05) differences *between Phase 1 and Phase 2* in the percent of providers reporting that COCs were ‘very safe’ or ‘safe’ versus ‘unsafe’ or ‘very unsafe’ versus ‘don’t know’ for the following groups of women? [Breastfeeding women ≥1 month postpartum without other risk factors for venous thromboembolism (VTE), Smokers 35 years of age or older, Obese women (BMI ≥30 kg/m2), Women with a history of bariatric surgery via restrictive procedures (e.g., vertical banded gastroplasty), Women with a history of bariatric surgery via malabsorptive procedures (e.g., Roux-en-Y gastric bypass), Women with rheumatoid arthritis, Women with inflammatory bowel disease (i.e., Ulcerative colitis, Crohn’s disease) without other risk factors for VTE]. NOTE: Those responding ‘don’t know’ may also be deleted from the analysis, or combined with the ‘unsafe/very unsafe’ group.  | Chi-square tests – overall, stratified by provider type [excluding non-Title X clinic providers who were not included in Phase 1], and stratified by awareness of the US MEC and use of US MEC provider tools (#31-32 in the phase 2 provider survey). |
| Phase 2 Provider Survey Question #14 |
| 2a | What percent of providers reported that COCs were ‘more effective’ or ‘equally effective’ versus ‘less effective’ versus ‘don’t know’ for the following groups of women compared to use by healthy women? [Obese women (BMI >30 kg/m2), Women with a history of bariatric surgery via restrictive procedures (e.g., vertical banded gastroplasty), Women with a history of bariatric surgery via malabsorptive procedures, (e.g., Roux-en-Y gastric bypass), Women on anticonvulsant therapy, Women on antibiotic therapy, Women with inflammatory bowel disease (i.e., Ulcerative colitis, Crohn’s disease)] | Frequencies – overall and stratified by provider type |
| 2b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting that COCs were ‘more effective’ or ‘equally effective’ versus ‘less effective’ versus ‘don’t know’ for the following groups of women compared to use by healthy women? [Obese women (BMI >30 kg/m2), Women with a history of bariatric surgery via restrictive procedures (e.g., vertical banded gastroplasty), Women with a history of bariatric surgery via malabsorptive procedures, (e.g., Roux-en-Y gastric bypass), Women on anticonvulsant therapy, Women on antibiotic therapy, Women with inflammatory bowel disease (i.e., Ulcerative colitis, Crohn’s disease)]NOTE: Those responding ‘don’t know’ may also be deleted from the analysis, or combined with the ‘unsafe/very unsafe’ group.  | Chi-square tests |
| Phase 2 Provider Survey Question #15 |
| 3a | What percent of providers reported that IUDs were ‘very safe’ or ‘safe’ versus ‘unsafe’ or ‘very unsafe’ versus ‘don’t know’ for the following groups of women *during Phase 2*? [Adolescents, Immediately postpartum women (less than 10 minutes after delivery of placenta, Postpartum women (10 minutes after delivery of placenta to less than 4 weeks postpartum), Nulliparous women, Obese women (BMI ≥30 kg/m2), Women with uterine fibroids, Women with HIV (not AIDS)] | Frequencies – overall and stratified by provider type |
| 3b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting that IUDs were ‘very safe’ or ‘safe’ versus ‘unsafe’ or ‘very unsafe’ versus ‘don’t know’ for the following groups of women *during Phase 2*? [Adolescents, Immediately postpartum women (less than 10 minutes after delivery of placenta, Postpartum women (10 minutes after delivery of placenta to less than 4 weeks postpartum), Nulliparous women, Obese women (BMI ≥30 kg/m2), Women with uterine fibroids, Women with HIV (not AIDS)]NOTE: Those responding ‘don’t know’ may also be deleted from the analysis, or combined with the ‘unsafe/very unsafe’ group.  | Chi-square tests |
| 3c | Are there significant (p<0.05) differences *between Phase 1 and Phase 2* in the percent of providers reporting that IUDs were ‘very safe’ or ‘safe’ versus ‘unsafe’ or ‘very unsafe’ versus ‘don’t know’ for the following groups of women? [Adolescents, Immediately postpartum women (less than 10 minutes after delivery of placenta, Postpartum women (10 minutes after delivery of placenta to less than 4 weeks postpartum), Nulliparous women, Obese women (BMI ≥30 kg/m2), Women with uterine fibroids, Women with HIV (not AIDS)]NOTE: Those responding ‘don’t know’ may also be deleted from the analysis, or combined with the ‘unsafe/very unsafe’ group.  | Chi-square tests – overall, stratified by provider type [excluding non-Title X clinic providers who were not included in Phase 1], and stratified by awareness of the US MEC and use of US MEC provider tools (#31-32 in the phase 2 provider survey). |
| Phase 2 Provider Survey Question #16 |
| 4a | What percent of providers reported that DMPA was ‘very safe’ or ‘safe’ versus ‘unsafe’ or ‘very unsafe’ versus ‘don’t know’ for the following groups of women *during Phase 2*? [Adolescents, Breastfeeding women <1month postpartum, Breastfeeding women ≥1 month postpartum, Smokers 35 years of age or older, Obese women (BMI ≥30 kg/m2), Women with a history of bariatric surgery via restrictive procedures, Women with rheumatoid arthritis not on immunosuppressive therapy, Women with inflammatory bowel disease, Women with complicated diabetes (i.e., nephropathy, retinopathy, neuropathy, other vascular disease or diabetes of >20 years’ duration) | Frequencies – overall and stratified by provider type |
| 4b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting that DMPA was ‘very safe’ or ‘safe’ versus ‘unsafe’ or ‘very unsafe’ versus ‘don’t know’ for the following groups of women *during Phase 2*? [Adolescents, Breastfeeding women <1month postpartum, Breastfeeding women ≥1 month postpartum, Smokers 35 years of age or older, Obese women (BMI ≥30 kg/m2), Women with a history of bariatric surgery via restrictive procedures, Women with rheumatoid arthritis not on immunosuppressive therapy, Women with inflammatory bowel disease, Women with complicated diabetes (i.e., nephropathy, retinopathy, neuropathy, other vascular disease or diabetes of >20 years’ duration)NOTE: Those responding ‘don’t know’ may also be deleted from the analysis, or combined with the ‘unsafe/very unsafe’ group.  | Chi-square tests |
| 4c | Are there significant (p<0.05) differences *between Phase 1 and Phase 2* in the percent of providers reporting that DMPA was ‘very safe’ or ‘safe’ versus ‘unsafe’ or ‘very unsafe’ versus ‘don’t know’ for the following groups of women? [Adolescents, Breastfeeding women <1month postpartum, Breastfeeding women ≥1 month postpartum, Smokers 35 years of age or older, Obese women (BMI ≥30 kg/m2), Women with a history of bariatric surgery via restrictive procedures, Women with rheumatoid arthritis not on immunosuppressive therapy, Women with inflammatory bowel disease, Women with complicated diabetes (i.e., nephropathy, retinopathy, neuropathy, other vascular disease or diabetes of >20 years’ duration)NOTE: Those responding ‘don’t know’ may also be deleted from the analysis, or combined with the ‘unsafe/very unsafe’ group.  | Chi-square tests – overall, stratified by provider type [excluding non-Title X clinic providers who were not included in Phase 1], and stratified by awareness of the US MEC and use of US MEC provider tools (#31-32 in the phase 2 provider survey). |
| Phase 2 Provider Survey Question #19 |
| 5a | What percent of providers reported providing DMPA to adolescents ‘very often or often’ versus ‘not often or never’ in the past year *during Phase 2*? | Frequencies – overall and stratified by provider type |
| 5b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting that they provided DMPA to adolescents ‘very often or often’ versus ‘not often or never’ in the past year *during Phase 2*?  | Chi-square tests |
| 5c | Are there significant (p<0.05) differences *between Phase 1 and Phase 2* in the percent of providers reporting that they provided DMPA to adolescents ‘very often or often’ versus ‘not often or never’ in the past year? | Chi-square tests – overall, stratified by provider type [excluding non-Title X clinic providers who were not included in Phase 1], and stratified by awareness of the US MEC and use of US MEC provider tools (#31-32 in the phase 2 provider survey). |
| 5d | Among providers reporting ‘not often or never’ providing DMPA to adolescents in the past year *during Phase 2*, what percent of providers reported various reasons why? [I rarely have adolescents as patients, DMPA is unavailable in my practice/health center, I am concerned about the safety of DMPA for adolescents, I am concerned about side effects that may lead to discontinuation, My adolescent patients generally prefer a different method, My practice/health center protocol does not allow it, Other reasons] | Frequencies – overall and stratified by provider type |
| Phase 2 Provider Survey Question #20 |
| 6a | What percent of providers reported providing COCs to breastfeeding women ≥1 month postpartum without other risk factors for VTE ‘very often or often’ versus ‘not often or never’ in the past year *during Phase 2*? | Frequencies – overall and stratified by provider type |
| 6b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting that they provided COCs to breastfeeding women ≥1 month postpartum without other risk factors for VTE ‘very often or often’ versus ‘not often or never’ in the past year *during Phase 2*?  | Chi-square tests |
| 6c | Are there significant (p<0.05) differences *between Phase 1 and Phase 2* in the percent of providers reporting that they provided COCs to breastfeeding women ≥1 month postpartum without other risk factors for VTE ‘very often or often’ versus ‘not often or never’ in the past year? | Chi-square tests – overall, stratified by provider type [excluding non-Title X clinic providers who were not included in Phase 1], and stratified by awareness of the US MEC and use of US MEC provider tools (#31-32 in the phase 2 provider survey). |
| 6d | Among providers reporting ‘not often or never’ providing COCs to breastfeeding women ≥1 month postpartum without other risk factors for VTE in the past year *during Phase 2*, what percent of providers reported various reasons why? [I rarely have postpartum women as patients, I am concerned about the safety of COCs for breastfeeding women ≥1 month postpartum without other risk factors for VTE, I am concerned about a decrease in breast milk production, My postpartum patients generally prefer a different method, My practice/health center protocol does not allow it, Other reasons] | Frequencies – overall and stratified by provider type |
| Phase 2 Provider Survey Question #21 |
| 7a | What percent of providers reported providing IUDs to nulliparous women ‘very often or often’ versus ‘not often or never’ in the past year *during Phase 2*? | Frequencies – overall and stratified by provider type |
| 7b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting that they provided IUDs to nulliparous women ‘very often or often’ versus ‘not often or never’ in the past year *during Phase 2*?  | Chi-square tests |
| 7c | Are there significant (p<0.05) differences *between Phase 1 and Phase 2* in the percent of providers reporting that they provided IUDs to nulliparous women ‘very often or often’ versus ‘not often or never’ in the past year? | Chi-square tests – overall, stratified by provider type [excluding non-Title X clinic providers who were not included in Phase 1], and stratified by awareness of the US MEC and use of US MEC provider tools (#31-32 in the phase 2 provider survey). |
| 7d | Among providers reporting ‘not often or never’ providing IUDs to nulliparous women in the past year *during Phase 2*, what percent of providers reported various reasons why? [I rarely have nulliparous women as patients, IUDs are generally unavailable in my practice/health center, I am concerned about the safety of IUDs for nulliparous women, I am concerned about difficult insertion, I am not trained in IUD insertion, My nulliparous patients generally prefer a different method, My practice/health center protocol does not allow it, Cost barriers prevent me from providing IUDs to nulliparous women, Other reasons] | Frequencies – overall and stratified by provider type |

| **PARAMETERS FOR OBJECTIVE 3** | **Statistical Approach** |
| --- | --- |
| Phase 2 Provider Survey Question #17 |
| 1a | What percent of providers reported that ‘Quick Start’ was ‘safe’ versus ‘unsafe’ versus ‘don’t know’ for ADOLESCENTS for the following contraceptive methods? [CHCs, DMPA, contraceptive implant, IUDs] | Frequencies – overall and stratified by provider type |
| 1b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting that ‘Quick Start’ was ‘safe’ versus ‘unsafe’ versus ‘don’t know’ for ADOLESCENTS for the following contraceptive methods? [CHCs, DMPA, contraceptive implant, IUDs]NOTE: Those responding ‘don’t know’ may also be deleted from the analysis, or combined with the ‘unsafe/very unsafe’ group.  | Chi-square tests |
| 1c | What percent of providers reported that ‘Quick Start’ was ‘safe’ versus ‘unsafe’ versus ‘don’t know’ for ADULTS for the following contraceptive methods? [CHCs, DMPA, contraceptive implant, IUDs] | Frequencies – overall and stratified by provider type |
| 1d | Are there significant (p<0.05) differences between provider types in the percent of providers reporting that ‘Quick Start’ was ‘safe’ versus ‘unsafe’ versus ‘don’t know’ for ADULTS for the following contraceptive methods? [CHCs, DMPA, contraceptive implant, IUDs]NOTE: Those responding ‘don’t know’ may also be deleted from the analysis, or combined with the ‘unsafe/very unsafe’ group.  | Chi-square tests |
| Phase 2 Provider Survey Question #18 |
| 2a | What percent of providers reported incorporating the following techniques ‘very often’ or ‘often’ versus ‘not often’ or ‘never’ when counseling a typical female patient of reproductive age in the past month? [Assessed the patient’s reproductive life plan, Presented information regarding potential contraceptive methods with the most effective methods presented first (tiered approach), Helped the patient think about potential barriers to using their selected method correctly and develop a plan to deal with these barriers, Use a method-specific informed consent form, Informed adolescents that long-acting reversible contraceptives are safe and effective options] | Frequencies – overall and stratified by provider type |
| 2b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting incorporating the following techniques ‘very often’ or ‘often’ versus ‘not often’ or ‘never’ when counseling a typical female patient of reproductive age in the past month? [Assessed the patient’s reproductive life plan, Presented information regarding potential contraceptive methods with the most effective methods presented first (tiered approach), Helped the patient think about potential barriers to using their selected method correctly and develop a plan to deal with these barriers, Use a method-specific informed consent form, Informed adolescents that long-acting reversible contraceptives are safe and effective options] | Chi-square tests |
| Phase 2 Provider Survey Question #22 |
| 3a | What percent of providers reported requiring a blood pressure exam when initiating the following contraceptive methods? [CHCs, POPs, DMPA, contraceptive implant, IUDs] | Frequencies – overall and stratified by provider type |
| 3b | Are there significant (p<0.05) differences between provider types in the percent of providers requiring a blood pressure exam when initiating the following contraceptive methods? [CHCs, POPs, DMPA, contraceptive implant, IUDs] | Chi-square tests |
| 4a | What percent of providers reported requiring a clinical breast exam when initiating the following contraceptive methods? [CHCs, POPs, DMPA, contraceptive implant, IUDs] | Frequencies – overall and stratified by provider type |
| 4b | Are there significant (p<0.05) differences between provider types in the percent of providers requiring a clinical breast exam when initiating the following contraceptive methods? [CHCs, POPs, DMPA, contraceptive implant, IUDs] | Chi-square tests |
| 5a | What percent of providers reported requiring a bimanual exam and cervical inspection when initiating the following contraceptive methods? [CHCs, POPs, DMPA, contraceptive implant, IUDs] | Frequencies – overall and stratified by provider type |
| 5b | Are there significant (p<0.05) differences between provider types in the percent of providers requiring a bimanual exam and cervical inspection when initiating the following contraceptive methods? [CHCs, POPs, DMPA, contraceptive implant, IUDs] | Chi-square tests |
| 6a | What percent of providers reported requiring a Pap smear when initiating the following contraceptive methods? [CHCs, POPs, DMPA, contraceptive implant, IUDs] | Frequencies – overall and stratified by provider type |
| 6b | Are there significant (p<0.05) differences between provider types in the percent of providers requiring a Pap smear when initiating the following contraceptive methods? [CHCs, POPs, DMPA, contraceptive implant, IUDs] | Chi-square tests |
| 7a | What percent of providers reported requiring chlamydia/gonorrhea screening when initiating the following contraceptive methods? [CHCs, POPs, DMPA, contraceptive implant, IUDs] | Frequencies – overall and stratified by provider type |
| 7b | Are there significant (p<0.05) differences between provider types in the percent of providers reported requiring chlamydia/gonorrhea screening when initiating the following contraceptive methods? [CHCs, POPs, DMPA, contraceptive implant, IUDs] | Chi-square tests |
| Phase 2 Provider Survey Question #23 |
| 8a | What percent of providers reported practicing ‘Quick Start’ of CHCs for ADOLESCENTS ‘very often or often’ versus ‘not often or never’ in the past year?  | Frequencies – overall and stratified by provider type |
| 8b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting practicing ‘Quick Start’ of CHCs for ADOLESCENTS ‘very often or often’ versus ‘not often or never’ in the past year?  | Chi-square tests |
| 8c | Among providers reporting ‘not often or never’ practicing ‘Quick Start’ of CHCs for ADOLESCENTS in the past year, what percent of providers reported various reasons why? [I do not think it is safe, I have liability concerns, I do not have enough training, I do not think it is appropriate for adolescents, My practice/health center does not allow it, Other] | Frequencies – overall and stratified by provider type |
| 9a | What percent of providers reported practicing ‘Quick Start’ of CHCs for ADULTS ‘very often or often’ versus ‘not often or never’ in the past year?  | Frequencies – overall and stratified by provider type |
| 9b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting practicing ‘Quick Start’ of CHCs for ADULTS ‘very often or often’ versus ‘not often or never’ in the past year?  | Chi-square tests |
| 9c | Among providers reporting ‘not often or never’ practicing ‘Quick Start’ of CHCs for ADULTS in the past year, what percent of providers reported various reasons why? [I do not think it is safe, I have liability concerns, I do not have enough training, I do not think it is appropriate for adults, My practice/health center does not allow it, Other] | Frequencies – overall and stratified by provider type |
| Phase 2 Provider Survey Question #24 |
| 10a | What percent of providers reported practicing ‘Quick Start’ of DMPA for ADOLESCENTS ‘very often or often’ versus ‘not often or never’ in the past year?  | Frequencies – overall and stratified by provider type |
| 10b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting practicing ‘Quick Start’ of DMPA for ADOLESCENTS ‘very often or often’ versus ‘not often or never’ in the past year?  | Chi-square tests |
| 10c | Among providers reporting ‘not often or never’ practicing ‘Quick Start’ of DMPA for ADOLESCENTS in the past year, what percent of providers reported various reasons why? [I do not think it is safe, I have liability concerns, I do not have enough training, I do not think it is appropriate for adolescents, My practice/health center does not allow it, Other] | Frequencies – overall and stratified by provider type |
| 11a | What percent of providers reported practicing ‘Quick Start’ of DMPA for ADULTS ‘very often or often’ versus ‘not often or never’ in the past year?  | Frequencies – overall and stratified by provider type |
| 11b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting practicing ‘Quick Start’ of DMPA for ADULTS ‘very often or often’ versus ‘not often or never’ in the past year?  | Chi-square tests |
| 11c | Among providers reporting ‘not often or never’ practicing ‘Quick Start’ of DMPA for ADULTS in the past year, what percent of providers reported various reasons why? [I do not think it is safe, I have liability concerns, I do not have enough training, I do not think it is appropriate for adults, My practice/health center does not allow it, Other] | Frequencies – overall and stratified by provider type |
| Phase 2 Provider Survey Question #25 |
| 12a | What percent of providers reported advising a healthy adult patient to come back for a follow-up visit ‘4-6 weeks’ ‘3 months’ ‘6 months’ ’12 months’ and ‘only if she has problems or questions’ after initiating the following methods? [CHCs, POPs, DMPA (routine follow-up other than for re-injection), implant, IUDs] | Frequencies – overall and stratified by provider type |
| 12b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting advising a healthy adult patient to come back for a follow-up visit ‘4-6 weeks’ ‘3 months’ ‘6 months’ ’12 months’ and ‘only if she has problems or questions’ after initiating the following methods? [CHCs, POPs, DMPA (routine follow-up other than for re-injection), implant, IUDs]NOTE: Some response options may be combined.  | Chi-square tests |
| Phase 2 Provider Survey Question #26 |
| 13a | What percent of providers reported providing an advance prescription for emergency contraception (EC) to a woman not specifically seeking EC ‘very often or often’ versus ‘not often or never’ in the past year?  | Frequencies – overall and stratified by provider type |
| 13b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting providing an advance prescription for emergency contraception (EC) to a woman not specifically seeking EC ‘very often or often’ versus ‘not often or never’ in the past year?  | Chi-square tests |
| 14a | What percent of providers reported providing an advance supply of EC to a woman not specifically seeking EC ‘very often or often’ versus ‘not often or never’ in the past year?  | Frequencies – overall and stratified by provider type |
| 14b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting providing an advance supply of EC to a woman not specifically seeking EC ‘very often or often’ versus ‘not often or never’ in the past year?  | Chi-square tests |
| 15a | What percent of providers reported providing or prescribing a contraceptive at the same time as providing EC ‘very often or often’ versus ‘not often or never’ in the past year?  | Frequencies – overall and stratified by provider type |
| 15b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting providing or prescribing a contraceptive at the same time as providing EC ‘very often or often’ versus ‘not often or never’ in the past year?  | Chi-square tests |
| 16a | What percent of providers reported providing a Cu-IUD as EC ‘very often or often’ versus ‘not often or never’ in the past year?  | Frequencies – overall and stratified by provider type |
| 16b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting providing a Cu-IUD as EC ‘very often or often’ versus ‘not often or never’ in the past year?  | Chi-square tests |
| Phase 2 Provider Survey Question #27 |
| 17a | What percent of providers reported dispensing a year’s supply of pills (COCs or POPs) at one visit for NEW USERS ‘very often or often’ versus ‘not often or never’ in the past year?  | Frequencies – overall and stratified by provider type |
| 17b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting dispensing a year’s supply of pills (COCs or POPs) at one visit for NEW USERS ‘very often or often’ versus ‘not often or never’ in the past year?  | Chi-square tests |
| 17c | Among providers reporting ‘not often or never’ dispensing a year’s supply of pills (COCs or POPs) at one visit for NEW USERS in the past year, what percent of providers reported various reasons why? [I do not think it is safe, My practice/health center does not dispense pills, My practice/health center protocol does not allow it, I have liability concerns, There is not enough supply in my practice/health center, I am concerned about wasting pill packs if the woman discontinues, Other] | Frequencies – overall and stratified by provider type |
| 18a | What percent of providers reported dispensing a year’s supply of pills (COCs or POPs) at one visit for CONTINUING USERS ‘very often or often’ versus ‘not often or never’ in the past year?  | Frequencies – overall and stratified by provider type |
| 18b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting dispensing a year’s supply of pills (COCs or POPs) at one visit for CONTINUING USERS ‘very often or often’ versus ‘not often or never’ in the past year?  | Chi-square tests |
| 18c | Among providers reporting ‘not often or never’ dispensing a year’s supply of pills (COCs or POPs) at one visit for CONTINUING USERS in the past year, what percent of providers reported various reasons why? [I do not think it is safe, My practice/health center does not dispense pills, My practice/health center protocol does not allow it, I have liability concerns, There is not enough supply in my practice/health center, I am concerned about wasting pill packs if the woman discontinues, Other] | Frequencies – overall and stratified by provider type |
| Phase 2 Provider Survey Question #29 |
| 19a | What percent of providers reported advising a woman to begin routine cervical cancer screening ‘whenever she becomes sexually active’, ‘starting at age 18’, ‘starting at age 21’, ‘don’t know’ and ‘other’? | Frequencies – overall and stratified by provider type |
| 19b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting advising a woman to begin routine cervical cancer screening ‘whenever she becomes sexually active’, ‘starting at age 18’, ‘starting at age 21’, ‘don’t know’ and ‘other’?NOTE: Some response options may be combined.  | Chi-square tests |
| Phase 2 Provider Survey Question #30 |
| 20a | What percent of providers reported providing cervical cancer screening for a sexually active, 25-year old patient with previously normal results ‘every visit’, ‘annually’, ‘every 2 years’, ‘every 3 years’, ‘don’t know’ and ‘other’? | Frequencies – overall and stratified by provider type |
| 20b | Are there significant (p<0.05) differences between provider types in the percent of providers reporting providing cervical cancer screening for a sexually active, 25-year old patient with previously normal results ‘every visit’, ‘annually’, ‘every 2 years’, ‘every 3 years’, ‘don’t know’ and ‘other’?NOTE: Some response options may be combined.  | Chi-square tests |
| Phase 2 Administrator Survey Question #9 |
| 21a | What percent of clinic administrators reported that the following methods were provided on site to clients who requested them in the past 3 months? [sterilization, IUDs, implant, DMPA, patch, ring, COCs, POPs, EC, condoms] | Frequencies – overall and stratified by clinic type |
| 21b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting that the following methods were provided on site to clients who requested them in the past 3 months? [sterilization, IUDs, implant, DMPA, patch, ring, COCs, POPs, EC, condoms] | Chi-square tests |
| 22a | What percent of clinic administrators reported that supplies for the following methods ran out in the past 3 months? [sterilization, IUDs, implant, DMPA, patch, ring, COCs, POPs, EC, condoms] | Frequencies – overall and stratified by clinic type |
| 22b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting that supplies for the following methods ran out in the past 3 months? [sterilization, IUDs, implant, DMPA, patch, ring, COCs, POPs, EC, condoms] | Chi-square tests |
| Phase 2 Administrator Survey Question #10 |
| 23a | What percent of clinic administrators reported that their health center provided the following services ‘never’, ‘rarely’, ‘occasionally’ and ‘frequently’? [Pregnancy diagnosis and counseling, Contraceptive services for women, Contraceptive services for men, Basic infertility services for women, Basic infertility services for men, STD screening for women, STD screening for mean, Preconception health care for women, Preconception health care for men] | Frequencies – overall and stratified by clinic type |
| 23b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting that their health center provided the following services ‘never’, ‘rarely’, ‘occasionally’ and ‘frequently’? [Pregnancy diagnosis and counseling, Contraceptive services for women, Contraceptive services for men, Basic infertility services for women, Basic infertility services for men, STD screening for women, STD screening for mean, Preconception health care for women, Preconception health care for men]NOTE: Some response options may be combined.  | Chi-square tests |
| Phase 2 Administrator Survey Question #11 |
| 24a | What percent of clinic administrators reported using the following referral practices ‘never’, ‘rarely’, ‘occasionally’ and ‘frequently’? [Provided a resource listing or directory to the client, Provided a documented referral to the client, Made an appointment for the client, Contracted the client directly about the referral outcome, Contacted the referral source to find out if the client was seen, Asked the client about the referral at his or her next visit] | Frequencies – overall and stratified by clinic type |
| 24b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting using the following referral practices ‘never’, ‘rarely’, ‘occasionally’ and ‘frequently’? [Provided a resource listing or directory to the client, Provided a documented referral to the client, Made an appointment for the client, Contracted the client directly about the referral outcome, Contacted the referral source to find out if the client was seen, Asked the client about the referral at his or her next visit]NOTE: Some response options may be combined.  | Chi-square tests |
| Phase 2 Administrator Survey Question #12 |
| 25a | What percent of clinic administrators reported that the following topics were part of routine screening during an initial or follow-up family planning visit as a standard of care for female clients? [Intimate partner and sexual violence, Alcohol and drug use, Tobacco use, Depression, Immunizations, Unhealthy diet, BMI, High blood pressure, Diabetes, High cholesterol, Chlamydia, Gonorrhea, Syphilis, HIV, Breast cancer, Cervical cancer] | Frequencies – overall and stratified by clinic type |
| 25b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting that the following topics were part of routine screening during an initial or follow-up family planning visit as a standard of care for female clients? [Intimate partner and sexual violence, Alcohol and drug use, Tobacco use, Depression, Immunizations, Unhealthy diet, BMI, High blood pressure, Diabetes, High cholesterol, Chlamydia, Gonorrhea, Syphilis, HIV, Breast cancer, Cervical cancer] | Chi-square tests |
| 26a | What percent of clinic administrators reported that the following topics were part of routine screening during an initial or follow-up family planning visit as specified in a written protocol (for females)? [Intimate partner and sexual violence, Alcohol and drug use, Tobacco use, Depression, Immunizations, Unhealthy diet, BMI, High blood pressure, Diabetes, High cholesterol, Chlamydia, Gonorrhea, Syphilis, HIV, Breast cancer, Cervical cancer] | Frequencies – overall and stratified by clinic type |
| 26b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting reported that the following topics were part of routine screening during an initial or follow-up family planning visit as specified in a written protocol (for females)? [Intimate partner and sexual violence, Alcohol and drug use, Tobacco use, Depression, Immunizations, Unhealthy diet, BMI, High blood pressure, Diabetes, High cholesterol, Chlamydia, Gonorrhea, Syphilis, HIV, Breast cancer, Cervical cancer] | Chi-square tests |
| 27a | What percent of clinic administrators reported that the following topics were part of routine screening during an initial or follow-up family planning visit as a standard of care for male clients? [Intimate partner and sexual violence, Alcohol and drug use, Tobacco use, Depression, Immunizations, Unhealthy diet, BMI, High blood pressure, Diabetes, High cholesterol, Chlamydia, Gonorrhea, Syphilis, HIV, Testicular cancer] | Frequencies – overall and stratified by clinic type |
| 27b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting that the following topics were part of routine screening during an initial or follow-up family planning visit as a standard of care for male clients? [Intimate partner and sexual violence, Alcohol and drug use, Tobacco use, Depression, Immunizations, Unhealthy diet, BMI, High blood pressure, Diabetes, High cholesterol, Chlamydia, Gonorrhea, Syphilis, HIV, Testicular cancer] | Chi-square tests |
| 28a | What percent of clinic administrators reported that the following topics were part of routine screening during an initial or follow-up family planning visit as specified in a written protocol (for males)? [Intimate partner and sexual violence, Alcohol and drug use, Tobacco use, Depression, Immunizations, Unhealthy diet, BMI, High blood pressure, Diabetes, High cholesterol, Chlamydia, Gonorrhea, Syphilis, HIV, Testicular cancer] | Frequencies – overall and stratified by clinic type |
| 28b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting that the following topics were part of routine screening during an initial or follow-up family planning visit as specified in a written protocol (for males)? [Intimate partner and sexual violence, Alcohol and drug use, Tobacco use, Depression, Immunizations, Unhealthy diet, BMI, High blood pressure, Diabetes, High cholesterol, Chlamydia, Gonorrhea, Syphilis, HIV, Testicular cancer] | Chi-square tests |
| Phase 2 Administrator Survey Question #13 |
| 29a | What percent of clinic administrators reported that certain techniques were considered the standard of care as part of contraceptive counseling? [Use open-ended questions, Assess the client’s RLP, Present information regarding potential contraceptive methods with the most effective methods presented first, Help the client think about potential barriers to using their selected method correctly and develop a plan to deal with these barriers, Use method-specific consent forms, Inform adolescents that LARCs are safe and effective options] | Frequencies – overall and stratified by clinic type |
| 29b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting that certain techniques were considered the standard of care as part of contraceptive counseling? [Use open-ended questions, Assess the client’s RLP, Present information regarding potential contraceptive methods with the most effective methods presented first, Help the client think about potential barriers to using their selected method correctly and develop a plan to deal with these barriers, Use method-specific consent forms, Inform adolescents that LARCs are safe and effective options] | Chi-square tests |
| 30a | What percent of clinic administrators reported that certain techniques were specified in a written protocol as recommendations for contraceptive counseling? [Use open-ended questions, Assess the client’s RLP, Present information regarding potential contraceptive methods with the most effective methods presented first, Help the client think about potential barriers to using their selected method correctly and develop a plan to deal with these barriers, Use method-specific consent forms, Inform adolescents that LARCs are safe and effective options] | Frequencies – overall and stratified by clinic type |
| 30b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting that certain techniques were specified in a written protocol as recommendations for contraceptive counseling? [Use open-ended questions, Assess the client’s RLP, Present information regarding potential contraceptive methods with the most effective methods presented first, Help the client think about potential barriers to using their selected method correctly and develop a plan to deal with these barriers, Use method-specific consent forms, Inform adolescents that LARCs are safe and effective options] | Chi-square tests |
| Phase 2 Administrator Survey Question #14 |
| 31a | What percent of clinic administrators reported that the following services or materials were available ‘never’, ‘rarely’, ‘occasionally’ and ‘frequently’? [Same-day appointments for clinical services, Weekend or evening hours for clinical services, Adolescent-only hours or days for clinical services, Educational materials specifically designed for adolescents, Educational materials in languages that match the needs of your client base, Language translation services that match the needs of your client base] | Frequencies – overall and stratified by clinic type |
| 31b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting that the following services or materials were available ‘never’, ‘rarely’, ‘occasionally’ and ‘frequently’? [Same-day appointments for clinical services, Weekend or evening hours for clinical services, Adolescent-only hours or days for clinical services, Educational materials specifically designed for adolescents, Educational materials in languages that match the needs of your client base, Language translation services that match the needs of your client base]NOTE: Some response options may be combined.  | Chi-square tests |
| Phase 2 Administrator Survey Question #15 |
| 32a | What percent of clinic administrators reported the following activities for adolescent clients in the past 3 months ‘never’, ‘rarely’, ‘occasionally’ and ‘frequently’? [Offered time alone with a provider for adolescents who came with a parent or guardian, Required parental consent for adolescents seeking contraceptive services, Actively encouraged communication between adolescents and parents/guardians about sex and reproductive health, Actively promoted the availability of confidential services to adolescents] | Frequencies – overall and stratified by clinic type |
| 32b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting the following activities for adolescent clients in the past 3 months ‘never’, ‘rarely’, ‘occasionally’ and ‘frequently’? [Offered time alone with a provider for adolescents who came with a parent or guardian, Required parental consent for adolescents seeking contraceptive services, Actively encouraged communication between adolescents and parents/guardians about sex and reproductive health, Actively promoted the availability of confidential services to adolescents]NOTE: Some response options may be combined.  | Chi-square tests |
| Phase 2 Administrator Survey Question #16 |
| 33a | What percent of clinic administrators reported using the following technologies ‘no’, ‘yes, limited use’ and ‘yes, routinely’? [Electronic health records, Electronic system for billing, Email, phone, or txt messages to clients for appointment reminders, Email, phone, or text messages to clients for test results, Website that allows clients to make appointments online] | Frequencies – overall and stratified by clinic type |
| 33b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting using the following technologies ‘no’, ‘yes, limited use’ and ‘yes, routinely’? [Electronic health records, Electronic system for billing, Email, phone, or txt messages to clients for appointment reminders, Email, phone, or text messages to clients for test results, Website that allows clients to make appointments online]NOTE: Some response options may be combined.  | Chi-square tests |
| Phase 2 Administrator Survey Question #17 |
| 34a | What percent of clinic administrators reported using the following methods for community education in the past 12 months? [TV, radio, Websites or social media, Billboards, Newspapers or magazines, Community events, Small group education (1 session), Small group education (2+ sessions with same group)] | Frequencies – overall and stratified by clinic type |
| 34b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting using the following methods for community education in the past 12 months? [TV, radio, Websites or social media, Billboards, Newspapers or magazines, Community events, Small group education (1 session), Small group education (2+ sessions with same group)] | Chi-square tests |
| Phase 2 Administrator Survey Question #18 |
| 35a | What percent of clinic administrators reported conducting community education in the following places or groups in the past 12 months? [Schools, Colleges or universities, Other youth-serving groups, Parent groups, Faith-based organizations, Other health care organization, Community health fairs, Other social service organizations] | Frequencies – overall and stratified by clinic type |
| 35b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting conducting community education in the following places or groups in the past 12 months? [Schools, Colleges or universities, Other youth-serving groups, Parent groups, Faith-based organizations, Other health care organization, Community health fairs, Other social service organizations] | Chi-square tests |
| Phase 2 Administrator Survey Question #19 |
| 36a | What percent of clinic administrators reported formally reviewing the following aspects of service delivery to monitor the quality of family planning services ‘monthly or quarterly’, ‘annually’, ‘every 2-3 years’, ‘as needed’, ‘other frequency’ and ‘never/not currently reviewed’? [Availability of contraceptive methods, Access to services, Clinic efficiency, Client satisfaction, Cultural competency, Referrals and/or care coordination, Contraceptive use, Cost of providing services, Unintended pregnancy, Birth spacing] | Frequencies – overall and stratified by clinic type |
| 36b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting formally reviewing the following aspects of service delivery to monitor the quality of family planning services ‘monthly or quarterly’, ‘annually’, ‘every 2-3 years’, ‘as needed’, ‘other frequency’ and ‘never/not currently reviewed’? [Availability of contraceptive methods, Access to services, Clinic efficiency, Client satisfaction, Cultural competency, Referrals and/or care coordination, Contraceptive use, Cost of providing services, Unintended pregnancy, Birth spacing]NOTE: Some response options may be combined.  | Chi-square tests |
| Phase 2 Administrator Survey Question #20 |
| 37 | What percent of clinic administrators reported specific modifications of clinical practices or other aspects of the health center in response to a review of quality improvement data ? (provider write-in responses) | Frequencies – overall and stratified by clinic type |
| Phase 2 Administrator Survey Question #21 |
| 38a | What percent of clinic administrators reported offering the following contraceptive methods and other services? [sterilization, IUD insertion/removal, Implant insertion/removal, Natural family planning, HIV treatment, Prenatal care, Primary care, Infertility treatment] | Frequencies – overall and stratified by clinic type |
| 38b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting offering the following contraceptive methods and other services? [sterilization, IUD insertion/removal, Implant insertion/removal, Natural family planning, HIV treatment, Prenatal care, Primary care, Infertility treatment] | Chi-square tests |
| 39a | What percent of clinic administrators reported partnerships *co-located* with providers who offer the following contraceptive methods and other services (or their parent organization provides)? [sterilization, IUD insertion/removal, Implant insertion/removal, Natural family planning, HIV treatment, Prenatal care, Primary care, Infertility treatment] | Frequencies – overall and stratified by clinic type |
| 39b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting partnerships *co-located* with providers who offer the following contraceptive methods and other services (or their parent organization provides)? [sterilization, IUD insertion/removal, Implant insertion/removal, Natural family planning, HIV treatment, Prenatal care, Primary care, Infertility treatment] | Chi-square tests |
| 40a | What percent of clinic administrators reported contracts or other written agreements with providers who offer the following contraceptive methods and other services (or their parent organization provides)? [sterilization, IUD insertion/removal, Implant insertion/removal, Natural family planning, HIV treatment, Prenatal care, Primary care, Infertility treatment] | Frequencies – overall and stratified by clinic type |
| 40b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting contracts or other written agreements with providers who offer the following contraceptive methods and other services? [sterilization, IUD insertion/removal, Implant insertion/removal, Natural family planning, HIV treatment, Prenatal care, Primary care, Infertility treatment] | Chi-square tests |
| 41a | What percent of clinic administrators reported informal relationships with providers who offer the following contraceptive methods and other? [sterilization, IUD insertion/removal, Implant insertion/removal, Natural family planning, HIV treatment, Prenatal care, Primary care, Infertility treatment] | Frequencies – overall and stratified by clinic type |
| 41b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting informal relationships with providers who offer the following contraceptive methods and other services? [sterilization, IUD insertion/removal, Implant insertion/removal, Natural family planning, HIV treatment, Prenatal care, Primary care, Infertility treatment] | Chi-square tests |
| 42a | What percent of clinic administrators reported the following contraceptive methods and other services through referral only? [sterilization, IUD insertion/removal, Implant insertion/removal, Natural family planning, HIV treatment, Prenatal care, Primary care, Infertility treatment] | Frequencies – overall and stratified by clinic type |
| 42b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting the following contraceptive methods and other services through referral only? [sterilization, IUD insertion/removal, Implant insertion/removal, Natural family planning, HIV treatment, Prenatal care, Primary care, Infertility treatment] | Chi-square tests |
| Phase 2 Administrator Survey Question #21 |
| 43a | What percent of clinic administrators reported that ‘all staff’, ‘some staff’, and ‘no staff’ were trained in the following areas? [Contraceptive counseling in the past 2 years, Serving male clients in the past 2 years, Inserting and removing copper IUDs (ever), Inserting and removing hormonal IUD (ever), Inserting and removing contraceptive implants (ever)]  | Frequencies – overall and stratified by clinic type |
| 43b | Are there significant (p<0.05) differences between clinic types in the percent of clinic administrators reporting that ‘all staff’, ‘some staff’, and ‘no staff’ were trained in the following areas? [Contraceptive counseling in the past 2 years, Serving male clients in the past 2 years, Inserting and removing copper IUDs (ever), Inserting and removing hormonal IUDs (ever), Inserting and removing contraceptive implants (ever)] | Chi-square tests |

# References

[1] Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. *Contraception*. 2011: in press,.

[2] Gipson JD, Koenig MA, Hindin MJ. The effects of unintended pregnancy on infant, child, and parental health: a review of the literature. *Studies in family planning*. 2008; **39**(1): 18-38.

[3] Trussell J. The cost of unintended pregnancy in the United States. *Contraception*. 2007; **75**(3): 168-70.

[4] Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. *PerspectSex ReprodHealth*. 2006; **38**(2): 90-6.

[5] Centers for Disease Control and Prevention. U S. Medical Eligibility Criteria for Contraceptive Use, 2010. *MMWR Recomm Rep*. 2010; **59**(RR-4): 1-86.

[6] World Health Organization. Selected Practice Recommendations for Contraceptive Use. 2nd edn. Geneva: WHO 2004.

[7] World Health Organization. Selected Practice Recommendations for Contraceptive Use 2008 Update. Geneva: WHO 2008.

[8] Office of Population Affairs. Program Guidelines for Project Grants for Family Planning Services Bethesda: OPA 2001.

[9] VanGeest JB, Johnson TP, Welch VL. Methodologies for improving response rates in surveys of physicians: a systematic review. *Eval Health Prof*. 2007; **30**(4): 303-21.

[10] Postlethwaite D, Shaber R, Mancuso V, Flores J, Armstrong MA. Intrauterine contraception: evaluation of clinician practice patterns in Kaiser Permanente Northern California. *Contraception*. 2007; **75**(3): 177-84.

[11] Harper CC, Blum M, de Bocanegra HT*, et al.* Challenges in translating evidence to practice: the provision of intrauterine contraception. *Obstet Gynecol*. 2008; **111**(6): 1359-69.

[12] Madden T, Allsworth JE, Hladky KJ, Secura GM, Peipert JF. Intrauterine contraception in Saint Louis: a survey of obstetrician and gynecologists' knowledge and attitudes. *Contraception*. 2010; **81**(2): 112-6.

[13] Espey E, Ogburn T, Leeman L, Reddy S, Lee C, Qualls C. Conformity with current guidelines on oral contraceptive prescribing for breastfeeding women: a New Mexico survey. *Contraception*. 2006; **74**(5): 389-93.

[14] Stanwood NL, Garrett JM, Konrad TR. Obstetrician-gynecologists and the intrauterine device: a survey of attitudes and practice. *Obstet Gynecol*. 2002; **99**(2): 275-80.

[15] Bureau of Labor Statistics. National Compensation Survey: December 2009 - January 2011. Bureau of Labor Statistics.